Pay in 4 interest-free payments of $20.00 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
Durisova K
at the transcriptional level
in 96-well plates and treated with PPZ for 24 h
1610408-97-3 ((S)(R)BAY-1251152)
Trelagliptin Catalog No.:M8519-10 Durisova KTrelagliptin, also known as SYR 472, is a long acting dipeptidyl peptidase 4 (DPP 4) inhibitor that is being developed by Takeda for the treatment of type 2 diabetes (T2D). Once weekly SYR 472 treatment produced clinically and statistically significant improvements in glycaemic control in patients with type 2 diabetes. It was well tolerated and might be a new treatment option for patients with this disease. Trelagliptin (Zafatek()) was approved in
US$ 17.99
US$ 29.99
US$ 18.99
US$ 28.99
US$ 24.99